Skip to main content
Top
Published in: Tumor Biology 4/2016

01-04-2016 | Original Article

MicroRNA-195 inhibits proliferation of cervical cancer cells by targeting cyclin D1a

Authors: Ning Wang, Heng Wei, Duo Yin, Yanming Lu, Yao Zhang, Qiao Zhang, Xiaoxin Ma, Shulan Zhang

Published in: Tumor Biology | Issue 4/2016

Login to get access

Abstract

Cervical cancer is one of the most frequent gynecological malignancies in women worldwide. MicroRNA-195 (miR-195) was recently found highly expressed in cervical cancer. However, the role of miR-195 in the pathology of cervical cancer remains poorly understood. In this study, we first confirmed the downregulation of miR-195 in primary cervical cancer tissues. For the functional study, we introduced the sequences of miR-195 or miR-195 inhibitor into Hela and SiHa cervical cancer cell lines. Overexpression of miR-195 inhibited the proliferation of both Hela and SiHa cells. In contrast, reducing the endogenous miR-195 level by miR-195 inhibitor promoted the proliferation of cervical cancer cells. Flow cytometric assay showed that overexpression of miR-195 induced G1 phase arrest, whereas miR-195 inhibitor shortened G1 phase of cervical cancer cells. In addition, the suppressive role of miR-195 in cell cycle was also demonstrated by the western blot results of various cell cycle indicators, such as phosphorylated retinoblastoma (p-Rb) and proliferating cell nuclear antigen (PCNA), in the gain and loss of function experiments. Furthermore, Dual-Luciferase Reporter Assay revealed that miR-195 targeted the 3′-untranslated region of cyclin D1a transcript, such as to regulate cyclin D1 expression. In summary, our results suggest that miR-195 acts as a suppressor in the proliferation and cell cycle of cervical cancer cells by directly targeting cyclin D1a mRNA.
Literature
1.
go back to reference Benard VB, Thomas CC, King J, Massetti GM, Doria-Rose VP, Saraiya M, et al. Vital signs: cervical cancer incidence, mortality, and screening—United States, 2007–2012. MMWR Morb Mortal Wkly Rep. 2014;63(44):1004–9.PubMed Benard VB, Thomas CC, King J, Massetti GM, Doria-Rose VP, Saraiya M, et al. Vital signs: cervical cancer incidence, mortality, and screening—United States, 2007–2012. MMWR Morb Mortal Wkly Rep. 2014;63(44):1004–9.PubMed
2.
go back to reference Wang SM, Qiao YL. Implementation of cervical cancer screening and prevention in China—challenges and reality. Jpn J Clin Oncol. 2015;45(1):7–11.CrossRefPubMed Wang SM, Qiao YL. Implementation of cervical cancer screening and prevention in China—challenges and reality. Jpn J Clin Oncol. 2015;45(1):7–11.CrossRefPubMed
3.
go back to reference Scheurer ME, Tortolero-Luna G, Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer. 2005;15(5):727–46.CrossRefPubMed Scheurer ME, Tortolero-Luna G, Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer. 2005;15(5):727–46.CrossRefPubMed
4.
go back to reference Dizon DS, Mackay HJ, Thomas GM, Werner TL, Kohn EC, Hess D, et al. State of the science in cervical cancer: where we are today and where we need to go. Cancer. 2014;120(15):2282–8.CrossRefPubMed Dizon DS, Mackay HJ, Thomas GM, Werner TL, Kohn EC, Hess D, et al. State of the science in cervical cancer: where we are today and where we need to go. Cancer. 2014;120(15):2282–8.CrossRefPubMed
5.
go back to reference Ramirez PT, Pareja R, Rendon GJ, Millan C, Frumovitz M, Schmeler KM. Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care? Gynecol Oncol. 2014;132(1):254–9.CrossRefPubMed Ramirez PT, Pareja R, Rendon GJ, Millan C, Frumovitz M, Schmeler KM. Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care? Gynecol Oncol. 2014;132(1):254–9.CrossRefPubMed
6.
8.
go back to reference Bhardwaj A, Singh S, Singh AP. MicroRNA-based cancer therapeutics: big hope from small RNAs. Mol Cell Pharmacol. 2010;2(5):213–9.PubMedPubMedCentral Bhardwaj A, Singh S, Singh AP. MicroRNA-based cancer therapeutics: big hope from small RNAs. Mol Cell Pharmacol. 2010;2(5):213–9.PubMedPubMedCentral
9.
go back to reference He JF, Luo YM, Wan XH, Jiang D. Biogenesis of miRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J Biochem Mol Toxicol. 2011;25(6):404–8.CrossRefPubMed He JF, Luo YM, Wan XH, Jiang D. Biogenesis of miRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J Biochem Mol Toxicol. 2011;25(6):404–8.CrossRefPubMed
10.
go back to reference Liu L, Chen L, Xu Y, Li R, Du X. MicroRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun. 2010;400(2):236–40.CrossRefPubMed Liu L, Chen L, Xu Y, Li R, Du X. MicroRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun. 2010;400(2):236–40.CrossRefPubMed
11.
go back to reference Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, et al. Analysis of miR-195 and miR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011;17(7):1722–30.CrossRefPubMed Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, et al. Analysis of miR-195 and miR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011;17(7):1722–30.CrossRefPubMed
12.
go back to reference Lin Y, Wu J, Chen H, Mao Y, Liu Y, Mao Q, et al. Cyclin-dependent kinase 4 is a novel target in microRNA-195-mediated cell cycle arrest in bladder cancer cells. FEBS Lett. 2012;586(4):442–7.CrossRefPubMed Lin Y, Wu J, Chen H, Mao Y, Liu Y, Mao Q, et al. Cyclin-dependent kinase 4 is a novel target in microRNA-195-mediated cell cycle arrest in bladder cancer cells. FEBS Lett. 2012;586(4):442–7.CrossRefPubMed
13.
go back to reference Zhang QQ, Xu H, Huang MB, Ma LM, Huang QJ, Yao Q, et al. MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro Oncol. 2012;14(3):278–87.CrossRefPubMedPubMedCentral Zhang QQ, Xu H, Huang MB, Ma LM, Huang QJ, Yao Q, et al. MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro Oncol. 2012;14(3):278–87.CrossRefPubMedPubMedCentral
14.
go back to reference Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology. 2009;50(1):113–21.CrossRefPubMed Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology. 2009;50(1):113–21.CrossRefPubMed
15.
go back to reference Sekiya Y, Ogawa T, Iizuka M, Yoshizato K, Ikeda K, Kawada N. Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-beta-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol. 2011;226(10):2535–42.CrossRefPubMed Sekiya Y, Ogawa T, Iizuka M, Yoshizato K, Ikeda K, Kawada N. Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-beta-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol. 2011;226(10):2535–42.CrossRefPubMed
16.
go back to reference Hui W, Yuntao L, Lun L, WenSheng L, ChaoFeng L, HaiYong H, et al. MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1. PLoS One. 2013;8(1), e54932.CrossRefPubMedPubMedCentral Hui W, Yuntao L, Lun L, WenSheng L, ChaoFeng L, HaiYong H, et al. MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1. PLoS One. 2013;8(1), e54932.CrossRefPubMedPubMedCentral
17.
go back to reference Park H, Lee MJ, Jeong JY, Choi MC, Jung SG, Joo WD, et al. Dysregulated microRNA expression in adenocarcinoma of the uterine cervix: clinical impact of miR-363-3p. Gynecol Oncol. 2014;135(3):565–72.CrossRefPubMed Park H, Lee MJ, Jeong JY, Choi MC, Jung SG, Joo WD, et al. Dysregulated microRNA expression in adenocarcinoma of the uterine cervix: clinical impact of miR-363-3p. Gynecol Oncol. 2014;135(3):565–72.CrossRefPubMed
18.
go back to reference Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20), e179.CrossRefPubMedPubMedCentral Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20), e179.CrossRefPubMedPubMedCentral
19.
go back to reference Oppitz U, Schulte S, Stopper H, Baier K, Muller M, Wulf J, et al. In vitro radiosensitivity measured in lymphocytes and fibroblasts by colony formation and comet assay: comparison with clinical acute reactions to radiotherapy in breast cancer patients. Int J Radiat Biol. 2002;78(7):611–6.CrossRefPubMed Oppitz U, Schulte S, Stopper H, Baier K, Muller M, Wulf J, et al. In vitro radiosensitivity measured in lymphocytes and fibroblasts by colony formation and comet assay: comparison with clinical acute reactions to radiotherapy in breast cancer patients. Int J Radiat Biol. 2002;78(7):611–6.CrossRefPubMed
21.
go back to reference Strzalka W, Ziemienowicz A. Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation. Ann Bot. 2011;107(7):1127–40.CrossRefPubMed Strzalka W, Ziemienowicz A. Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation. Ann Bot. 2011;107(7):1127–40.CrossRefPubMed
22.
go back to reference Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009;24(4):652–7.CrossRefPubMed Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009;24(4):652–7.CrossRefPubMed
23.
go back to reference Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251(3):499–505.CrossRefPubMed Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251(3):499–505.CrossRefPubMed
24.
go back to reference Hansen J, Bross P. A cellular viability assay to monitor drug toxicity. Methods Mol Biol. 2010;648:303–11.CrossRefPubMed Hansen J, Bross P. A cellular viability assay to monitor drug toxicity. Methods Mol Biol. 2010;648:303–11.CrossRefPubMed
25.
go back to reference Liu D, Feng X, Wu X, Li Z, Wang W, Tao Y, et al. Tumor suppressor in lung cancer 1 (TSLC1), a novel tumor suppressor gene, is implicated in the regulation of proliferation, invasion, cell cycle, apoptosis, and tumorigenicity in cutaneous squamous cell carcinoma. Tumour Biol. 2013;34(6):3773–83.CrossRefPubMed Liu D, Feng X, Wu X, Li Z, Wang W, Tao Y, et al. Tumor suppressor in lung cancer 1 (TSLC1), a novel tumor suppressor gene, is implicated in the regulation of proliferation, invasion, cell cycle, apoptosis, and tumorigenicity in cutaneous squamous cell carcinoma. Tumour Biol. 2013;34(6):3773–83.CrossRefPubMed
26.
go back to reference Park MT, Lee SJ. Cell cycle and cancer. J Biochem Mol Biol. 2003;36(1):60–5.PubMed Park MT, Lee SJ. Cell cycle and cancer. J Biochem Mol Biol. 2003;36(1):60–5.PubMed
27.
go back to reference Arato-Ohshima T, Sawa H. Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility. Int J Cancer. 1999;83(3):387–92.CrossRefPubMed Arato-Ohshima T, Sawa H. Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility. Int J Cancer. 1999;83(3):387–92.CrossRefPubMed
28.
go back to reference Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 2004;9(1):95–104.CrossRefPubMed Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 2004;9(1):95–104.CrossRefPubMed
29.
go back to reference Chakravarti A, Delaney MA, Noll E, Black PM, Loeffler JS, Muzikansky A, et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res. 2001;7(8):2387–95.PubMed Chakravarti A, Delaney MA, Noll E, Black PM, Loeffler JS, Muzikansky A, et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res. 2001;7(8):2387–95.PubMed
Metadata
Title
MicroRNA-195 inhibits proliferation of cervical cancer cells by targeting cyclin D1a
Authors
Ning Wang
Heng Wei
Duo Yin
Yanming Lu
Yao Zhang
Qiao Zhang
Xiaoxin Ma
Shulan Zhang
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4292-3

Other articles of this Issue 4/2016

Tumor Biology 4/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine